289 related articles for article (PubMed ID: 29327406)
1. Short and medium-term efficacy of sodium glucose co-transporter-2 (SGLT-2) inhibitors: A meta-analysis of randomized clinical trials.
Monami M; Liistro F; Scatena A; Nreu B; Mannucci E
Diabetes Obes Metab; 2018 May; 20(5):1213-1222. PubMed ID: 29327406
[TBL] [Abstract][Full Text] [Related]
2. Efficacy and safety of sodium-glucose cotransporter-2 inhibitors versus dipeptidyl peptidase-4 inhibitors as monotherapy or add-on to metformin in patients with type 2 diabetes mellitus: A systematic review and meta-analysis.
Wang Z; Sun J; Han R; Fan D; Dong X; Luan Z; Xiang R; Zhao M; Yang J
Diabetes Obes Metab; 2018 Jan; 20(1):113-120. PubMed ID: 28656707
[TBL] [Abstract][Full Text] [Related]
3. Should Baseline Hemoglobin A
Uhrig JL; Page SO; Mishriky BM; Patil SP; Powell JR; Sewell K; Mian MR; Cummings DM
J Clin Pharmacol; 2020 Aug; 60(8):980-991. PubMed ID: 32396236
[TBL] [Abstract][Full Text] [Related]
4. Comparative effectiveness of second line oral antidiabetic treatments among people with type 2 diabetes mellitus: emulation of a target trial using routinely collected health data.
Bidulka P; Lugo-Palacios DG; Carroll O; O'Neill S; Adler AI; Basu A; Silverwood RJ; Bartlett JW; Nitsch D; Charlton P; Briggs AH; Smeeth L; Douglas IJ; Khunti K; Grieve R
BMJ; 2024 May; 385():e077097. PubMed ID: 38719492
[TBL] [Abstract][Full Text] [Related]
5. Adding Sodium-Glucose Co-Transporter 2 Inhibitors to Sulfonylureas and Risk of Hypoglycemia: A Systematic Review and Meta-Analysis of Randomized Controlled Trials.
Jiang M; Liu Q; Jiang T; Nizigiyimana P; Lei M
Front Endocrinol (Lausanne); 2021; 12():713192. PubMed ID: 34744998
[TBL] [Abstract][Full Text] [Related]
6. Glucose-lowering agents for treating pre-existing and new-onset diabetes in kidney transplant recipients.
Lo C; Toyama T; Oshima M; Jun M; Chin KL; Hawley CM; Zoungas S
Cochrane Database Syst Rev; 2020 Jul; 8(8):CD009966. PubMed ID: 32803882
[TBL] [Abstract][Full Text] [Related]
7. Ertugliflozin plus sitagliptin versus either individual agent over 52 weeks in patients with type 2 diabetes mellitus inadequately controlled with metformin: The VERTIS FACTORIAL randomized trial.
Pratley RE; Eldor R; Raji A; Golm G; Huyck SB; Qiu Y; Sunga S; Johnson J; Terra SG; Mancuso JP; Engel SS; Lauring B
Diabetes Obes Metab; 2018 May; 20(5):1111-1120. PubMed ID: 29266675
[TBL] [Abstract][Full Text] [Related]
8. Tofogliflozin decreases body fat mass and improves peripheral insulin resistance.
Matsuba R; Matsuba I; Shimokawa M; Nagai Y; Tanaka Y
Diabetes Obes Metab; 2018 May; 20(5):1311-1315. PubMed ID: 29316197
[TBL] [Abstract][Full Text] [Related]
9. Head-to-head comparison of dipeptidyl peptidase-IV inhibitors and sulfonylureas - a meta-analysis from randomized clinical trials.
Zhang Y; Hong J; Chi J; Gu W; Ning G; Wang W
Diabetes Metab Res Rev; 2014 Mar; 30(3):241-56. PubMed ID: 24123720
[TBL] [Abstract][Full Text] [Related]
10. Efficacy and safety of sodium glucose co-transport-2 inhibitors in type 2 diabetes: a meta-analysis of randomized clinical trials.
Monami M; Nardini C; Mannucci E
Diabetes Obes Metab; 2014 May; 16(5):457-66. PubMed ID: 24320621
[TBL] [Abstract][Full Text] [Related]
11. Incretin mimetics and sodium-glucose co-transporter 2 inhibitors as monotherapy or add-on to metformin for treatment of type 2 diabetes: a systematic review and network meta-analysis.
Jia S; Wang Z; Han R; Zhang Z; Li Y; Qin X; Zhao M; Xiang R; Yang J
Acta Diabetol; 2021 Jan; 58(1):5-18. PubMed ID: 32514989
[TBL] [Abstract][Full Text] [Related]
12. Comparing SGLT-2 inhibitors to DPP-4 inhibitors as an add-on therapy to metformin in patients with type 2 diabetes: A systematic review and meta-analysis.
Mishriky BM; Tanenberg RJ; Sewell KA; Cummings DM
Diabetes Metab; 2018 Mar; 44(2):112-120. PubMed ID: 29477373
[TBL] [Abstract][Full Text] [Related]
13. Two years with GIOIA 'Effects of gliflozins and gliptins on markers of cardiovascular damage in type 2 diabetes': A prospective, multicentre, quasi-experimental study on sodium-glucose cotransporter 2 and dipeptidyl peptidase-4 inhibitors in diabetes clinical practice.
Longo M; Caruso P; Scappaticcio L; Maiorino MI; Bellastella G; Capuano A; Esposito K; Giugliano D
Diabetes Obes Metab; 2024 Apr; 26(4):1492-1501. PubMed ID: 38234208
[TBL] [Abstract][Full Text] [Related]
14. SGLT-2 Inhibitors and DPP-4 Inhibitors as Second-Line Drugs in Patients with Type 2 Diabetes: A Meta-Analysis of Randomized Clinical Trials.
Wang K; Zhang Y; Zhao C; Jiang M
Horm Metab Res; 2018 Oct; 50(10):768-777. PubMed ID: 30261527
[TBL] [Abstract][Full Text] [Related]
15. Dipeptidyl peptidase-4 inhibitors for treatment of type 2 diabetes mellitus in the clinical setting: systematic review and meta-analysis.
Karagiannis T; Paschos P; Paletas K; Matthews DR; Tsapas A
BMJ; 2012 Mar; 344():e1369. PubMed ID: 22411919
[TBL] [Abstract][Full Text] [Related]
16. Estimating the effect of sulfonylurea on HbA1c in diabetes: a systematic review and meta-analysis.
Hirst JA; Farmer AJ; Dyar A; Lung TW; Stevens RJ
Diabetologia; 2013 May; 56(5):973-84. PubMed ID: 23494446
[TBL] [Abstract][Full Text] [Related]
17. Predictors of response to dipeptidyl peptidase-4 inhibitors: evidence from randomized clinical trials.
Monami M; Cremasco F; Lamanna C; Marchionni N; Mannucci E
Diabetes Metab Res Rev; 2011 May; 27(4):362-72. PubMed ID: 21309062
[TBL] [Abstract][Full Text] [Related]
18. Long-term safety and efficacy of canagliflozin as add-on therapy to teneligliptin in Japanese patients with type 2 diabetes.
Kadowaki T; Inagaki N; Kondo K; Nishimura K; Kaneko G; Maruyama N; Nakanishi N; Watanabe Y; Gouda M; Iijima H
Diabetes Obes Metab; 2018 Jan; 20(1):77-84. PubMed ID: 28608617
[TBL] [Abstract][Full Text] [Related]
19. The placebo response of injectable GLP-1 receptor agonists vs. oral DPP-4 inhibitors and SGLT-2 inhibitors: a systematic review and meta-analysis.
de Wit HM; Te Groen M; Rovers MM; Tack CJ
Br J Clin Pharmacol; 2016 Jul; 82(1):301-14. PubMed ID: 26935973
[TBL] [Abstract][Full Text] [Related]
20. Sodium-glucose co-transporter inhibitors as adjunctive treatment to insulin in type 1 diabetes: A review of randomized controlled trials.
Boeder S; Edelman SV
Diabetes Obes Metab; 2019 Apr; 21 Suppl 2(Suppl 2):62-77. PubMed ID: 31081593
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
